Safety is of great importance as efficacy in assessing the role of an innovative combination due to most patients with advanced NSCLC ultimately die of their cancer, such as SFI plus EGFR-TKIs studied in this current research. This evidence concerns the gene EGFR and non-small cell lung carcinoma.